$0.04
(Market cap
$455 Mln
Revenue (TTM)
$83 Mln
P/E Ratio
--
P/B Ratio
8.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.5 %
-
ROCE
-- %
-
Industry P/E
44.46
-
EV/EBITDA
-4.2
-
Debt to Equity
0.6
-
Book Value
$--
-
EPS
$-0.6
-
Face value
--
-
Shares outstanding
55,087,990
6 Years Aggregate
CFO
$-247.34 Mln
EBITDA
$-266.31 Mln
Net Profit
$-279.60 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Sight Sciences Inc (SGHT)
| 6.1 | 71.3 | 68.5 | 98.8 | 9.6 | -24.4 | -- |
|
BSE Sensex*
| -8.8 | 0.5 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Sight Sciences Inc (SGHT)
| 117.9 | -29.3 | -57.7 | -30.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Sight Sciences Inc (SGHT)
|
8.4 | 455.0 | 83.4 | -29.8 | -31.4 | -50.9 | -- | 8.5 |
| 64.9 | 8,484.6 | 616.9 | -75.1 | 1.7 | -9.3 | -- | 10.1 | |
| 14.6 | 9,638.1 | 6,561.1 | -578.0 | -4.5 | -10.3 | -- | 1.7 | |
| 365.1 | 9,761.6 | 2,589.3 | 222.4 | -6.0 | 3 | 44.5 | 1.3 | |
| 59.3 | 9,074.5 | 3,499.6 | -71.2 | 0.5 | -3.2 | -- | 3.8 | |
| 181.9 | 10,905.5 | 612.8 | -188.1 | -30.6 | -28.1 | -- | 16.4 | |
| 100.5 | 6,525.3 | 1,556.3 | 275.3 | 24.6 | 22.9 | 24 | 5.0 | |
| 321.0 | 12,752.7 | 1,504.9 | 160.6 | 13.6 | 10.9 | 79.4 | 8.4 | |
| 182.0 | 10,222.2 | 785.1 | 41.5 | 9.9 | 2 | 251.6 | 4.8 | |
| 29.1 | 12,153.4 | 6,164.0 | 625.0 | 13.0 | 11.8 | 19.9 | 2.4 |
Shareholding Pattern
View DetailsAbout Sight Sciences Inc (SGHT)
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two... segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists. It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California. Read more
-
Co-Founder, President, CEO & Director
Mr. Paul Badawi
-
Co-Founder, President, CEO & Director
Mr. Paul Badawi
-
Headquarters
Menlo Park, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Sight Sciences Inc (SGHT)
What is the current share price of Sight Sciences Inc (SGHT) Today?
The share price of Sight Sciences Inc (SGHT) is $8.41 (NASDAQ) as of 27-Aug-2026 16:00 EDT. Sight Sciences Inc (SGHT) has given a return of 9.65% in the last 3 years.
What is the current PB & PE ratio of Sight Sciences Inc (SGHT)?
Since, TTM earnings of Sight Sciences Inc (SGHT) is negative, P/E ratio is not available.
The P/B ratio of Sight Sciences Inc (SGHT) is 8.48 times as on 21-Aug-2026, a 121 premium to its peers’ median range of 3.84 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-10.95 |
6.58 |
2024 |
-3.59 |
2.11 |
2023 |
-4.54 |
2.10 |
2022 |
-6.82 |
3.68 |
2021 |
-13.23 |
3.59 |
What is the 52 Week High and Low of Sight Sciences Inc (SGHT)?
The 52-week high and low of Sight Sciences Inc (SGHT) are Rs 9.24 and Rs 3.19 as of 28-Aug-2026.
What is the market cap of Sight Sciences Inc (SGHT)?
Sight Sciences Inc (SGHT) has a market capitalisation of $ 455 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Sight Sciences Inc (SGHT)?
Before investing in Sight Sciences Inc (SGHT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.